Recombinant allergens are produced both in prokaryotic (mainly E. coli) and in eukaryotic (yeast and insect cells) expression systems and in addition to their use in diagnostics find their way also into immunotherapy of various allergies.
The mouse monoclonal antibody JOVI.1, recognizing an extracellular epitope on TCR Cbeta1 (TRBC1), is suitable for flow cytometry, immunoprecipitation, and immunohistochemistry (frozen sections). It is popular as a tool for analysis of T cell-mediated diseases.
We are proud to inform you that in March 2020 in Cytometry B (Clinical cytometry) a paper was released having one of our colleagues from EXBIO Praha team Miro Benko (Director, Product Development Department) as a co-author.
Recently developed strategy for prevention of cancer relapse due to acquired radioresistance may be based on immunotherapies. One promising approach is based on genetically modified T cells expressing chimeric antigen receptors (CAR).
EXBIO has recently developed two new products for multicolor flow-cytometric immunophenotyping of cells of the human immune system from peripheral blood to follow up kinetics of immune responses in relation to clinical and virological features of a COVID-19 patients.
Now, we bring you a presentation of patient’s data – comparision with percentage range acquired from normal healthy donors and time-course changes in subpopulations of B and T cells of hospitalized patients diagnosed with COVID-19.